ACEI/ARBs Up AMI Outcomes Regardless of Renal Status

Share this content:
ACEI/ARBs Up AMI Outcomes Regardless of Renal Status
ACEI/ARBs Up AMI Outcomes Regardless of Renal Status

FRIDAY, April 8, 2016 (HealthDay News) -- For acute myocardial infarction (AMI) survivors, angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) treatment is associated with improved long-term survival, according to research published in the April 12 issue of the Journal of the American College of Cardiology.

Marie Evans, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues examined discharge and continuous follow-up data on ACEI/ARB use among AMI survivors (2006 to 2009) from a large Swedish registry.

The researchers found that 45,697 patients (71 percent) were treated with ACEI/ARB. Overall, the three-year mortality was 19.8 percent (17.4 and 25.4 percent among users and non-users, respectively). Survival was significantly better for patients treated with ACEI/ARB in adjusted analysis (three-year hazard ratio, 0.80), with survival benefit consistent across all kidney function strata, including dialysis patients. The three-year risk for myocardial infarction was lower for those treated with ACEI/ARB (hazard ratio, 0.91), while no significant effect was seen for stroke risk. In general, the crude risk for acute kidney injury (AKI) was low (2.5 for treated and 2.0 for non-treated patients), and was similar across categories of estimate glomerular filtration rate; the risk was significantly higher with ACEI/ARB treatment. ACEI/ARB treatment was favored for the composite of AKI and mortality.

"Treatment with ACEI/ARB after AMI was associated with improved long-term survival, regardless of underlying renal function, and was accompanied by low rates of adverse renal events," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »